Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 170 of 5804
-
Could a targeted drug shrink advanced cervical tumors?
Disease control CompletedAssess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical cancer (CC) after failure of platinum-based regimen treatment.
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New daily pill aims to tame Crohn's Flare-Ups
Disease control TerminatedThis is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adult participants with moderately to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the curre…
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Heated chemo during surgery may boost ovarian cancer survival
Disease control Ongoingstage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy
Phase: PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Drug duo targets Hard-to-Treat IDH-Mutated tumors
Disease control OngoingThis is a phase 2 study of the combination of drugs olaparib and durvalumab for the treatment of isocitrate dehydrogenase or (IDH) mutated solid tumors. The purpose of this study is to assess the efficacy of the drug combination via overall response rate and overall disease contr…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a single infusion of 'Trainer' cells free liver transplant patients from lifelong drugs?
Disease control CompletedPhase I/II, single center, prospective, open-label, non-controlled, non-randomized, interventional, cohort study in which low risk living donor liver transplant (LDLT) recipients who are between 1 and 3 years after transplantation and meet specific criteria (no positive crossmatc…
Phase: PHASE1, PHASE2 • Sponsor: Angus W. Thomson PhD DSc • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New antibiotic coating could shield heart surgery patients from dangerous infections
Prevention TerminatedProspective, Multinational, Multicenter, Randomized, Parallel Controlled, Two arms, Single Blind, Study to Assess the Efficacy and Safety of D-PLEX Administered Concomitantly with the Standard of Care (SOC) IV Prophylactic Antibiotic Treatment vs. SOC in Prevention of Post-Cardia…
Phase: PHASE3 • Sponsor: PolyPid Ltd. • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
New pill could cut recurrence risk in aggressive breast cancer
Disease control Recruiting nowThis is a prospective, randomised, multicenter, no placebo-controlled, open label study for evaluating the efficacy and safety of pyrotinib in women with residual invasive HER2-positive breast cancer after neoadjuvant chemotherapy plus anti-HER2 target therapy. The main purpose i…
Phase: PHASE3 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:06 UTC
-
Surgery or pills? new study tests best way to treat teen diabetes
Disease control OngoingThis study will test the hypothesis that metabolic bariatric surgery will be more effective at providing durable glycemic control and reduce co-morbidities than intensive medical therapy in youth with type 2 diabetes.
Phase: PHASE4 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New shot could tame uncontrollable itch of prurigo nodularis
Disease control CompletedPrimary Objective: To demonstrate the efficacy of dupilumab on itch response in participants with prurigo nodularis (PN), inadequately controlled on topical prescription therapies or when those therapies are not advisable. Secondary Objectives: To demonstrate the efficacy of d…
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 18:24 UTC
-
New drug gilteritinib takes on standard therapy in FLT3 leukemia trial
Disease control CompletedEligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during in…
Phase: PHASE2 • Sponsor: PrECOG, LLC. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo attack on eye cancer that spreads to the liver
Disease control OngoingMelanoma of the eye (ocular/uveal melanoma) is an uncommon type of cancer that is associated with a high mortality. It usually disseminates rapidly throughout the body, most commonly to the liver and lungs. In this study a combination therapy with immunotherapy (ipilimumab with n…
Phase: PHASE1, PHASE2 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Combining two drugs may tackle bladder cancer that resists standard therapy
Disease control OngoingThis study will test the safety of BCG and gemcitabine in people who have BCG-relapsing Non-Muscle Invasive Bladder Cancer (NMIBC). The researchers will test increasing doses of gemcitabine to find the highest dose that causes few or mild side effects when combined with BCG. The …
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New antibody drug shows promise against Hard-to-Treat lymphoma
Disease control OngoingThis study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. …
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo may let CML patients pause treatment
Disease control OngoingThe investigators hypothesize that, in newly diagnosed de novo chronic phase CML patients, an induction treatment with ponatinib for 6 months should increase the rate of patients reaching a stable MR4.5 allowing cessation of imatinib treatment. The investigators proposal is to c…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Freeze and boost: new combo aims to stop breast cancer return
Disease control OngoingThe purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after ta…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for tough leukemias: experimental pill targets genetic weakness
Disease control Recruiting nowPhase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- an…
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cocktail aims to stall lung cancer progression
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with metastatic nonsquamous non-small cell lung cancer. …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 26, 2026 14:55 UTC
-
New drug cocktail aims to beat back stubborn leukemia
Disease control Recruiting nowThis study involves evaluating a combination of chemotherapy drugs known as "CLAG-GO" \[cladribine, cytarabine, granulocyte-colony stimulating factor (G-CSF) and gemtuzumab ozogamicin (GO)\] in the treatment of acute myeloid leukemia (AML) that has not responded well to standard …
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
High-Dose radiation may extend life for patients with a few cancer spots
Disease control OngoingStereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR…
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug could simplify treatment for rare EGPA disease
Disease control OngoingThis is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC